Literature DB >> 25820066

Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.

Jon Oscherwitz1, Conrad P Quinn2, Kemp B Cease3.   

Abstract

BACKGROUND: Epitope-focused immunogens can elicit antibody against the loop neutralizing determinant (LND), a neutralizing epitope found within the 2β2-2β3 loop of protective antigen (PA), which can protect rabbits from high-dose inhalation challenge with Bacillus anthracis Ames strain. Interestingly, data suggests that this epitope is relatively immunosilent in rabbits and non-human primates immunized with full length PA.
METHODS: To determine whether the LND is immunosilent among humans vaccinated with PA, we screened antisera from AVA- or placebo-vaccinees from a clinical trial for antibody reactive with the LND.
RESULTS: AVA-vaccinee sera had significant PA-specific antibody compared to placebo-vaccinee sera; however, sera from the two cohorts were indistinguishable with regard to the frequency of individuals with antibody specific for the LND.
CONCLUSIONS: AVA-vaccinees have a low frequency of antibody reactive with the LND. As with rabbits and non-human primates, the elicitation of LND-specific antibody in humans appears to require immunization with an epitope-focused vaccine.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AVA; Antibody; Epitope; Protective antigen; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 25820066      PMCID: PMC4519083          DOI: 10.1016/j.vaccine.2015.03.037

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  A dominant negative mutant of Bacillus anthracis protective antigen inhibits anthrax toxin action in vivo.

Authors:  Y Singh; H Khanna; A P Chopra; V Mehra
Journal:  J Biol Chem       Date:  2001-03-16       Impact factor: 5.157

3.  Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge.

Authors:  Michael P Fay; Dean A Follmann; Freyja Lynn; Jarad M Schiffer; Gregory V Stark; Robert Kohberger; Conrad P Quinn; Edwin O Nuzum
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

4.  Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Authors:  S F Little; B E Ivins; P F Fellows; A M Friedlander
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

5.  The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor.

Authors:  Y Singh; K R Klimpel; N Arora; M Sharma; S H Leppla
Journal:  J Biol Chem       Date:  1994-11-18       Impact factor: 5.157

6.  Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.

Authors:  Nina Marano; Brian D Plikaytis; Stacey W Martin; Charles Rose; Vera A Semenova; Sandra K Martin; Alison E Freeman; Han Li; Mark J Mulligan; Scott D Parker; Janiine Babcock; Wendy Keitel; Hana El Sahly; Gregory A Poland; Robert M Jacobson; Harry L Keyserling; Stephen D Soroka; Sarah P Fox; John L Stamper; Michael M McNeil; Bradley A Perkins; Nancy Messonnier; Conrad P Quinn
Journal:  JAMA       Date:  2008-10-01       Impact factor: 56.272

7.  Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.

Authors:  M J Rosovitz; Peter Schuck; Mini Varughese; Arun P Chopra; Varsha Mehra; Yogendra Singh; Lisa M McGinnis; Stephen H Leppla
Journal:  J Biol Chem       Date:  2003-05-27       Impact factor: 5.157

Review 8.  Anthrax toxin.

Authors:  R John Collier; John A T Young
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

9.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed.

Authors:  Donald Reason; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Infect Immun       Date:  2009-02-17       Impact factor: 3.441

View more
  3 in total

1.  The promise and challenge of epitope-focused vaccines.

Authors:  Jon Oscherwitz
Journal:  Hum Vaccin Immunother       Date:  2016-04-08       Impact factor: 3.452

2.  Immunological Evidence of Variation in Exposure and Immune Response to Bacillus anthracis in Herbivores of Kruger and Etosha National Parks.

Authors:  Sunday O Ochai; Jan E Crafford; Ayesha Hassim; Charles Byaruhanga; Yen-Hua Huang; Axel Hartmann; Edgar H Dekker; O Louis van Schalkwyk; Pauline L Kamath; Wendy C Turner; Henriette van Heerden
Journal:  Front Immunol       Date:  2022-02-14       Impact factor: 7.561

3.  Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis.

Authors:  Sean M Kelly; Kristina R Larsen; Ross Darling; Andrew C Petersen; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Vaccine       Date:  2021-06-02       Impact factor: 4.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.